source
- Biogen reports mixed Alzheimer’s trial results as industry sees new startup launchesBiogen released data from its Alzheimer’s program that showed mixed outcomes, indicating some signals but also setbacks. The weekly newsletter also highlighted the launch of two new biotech startu…
- FDA approves Lipfendra, first oral PCSK9 inhibitor, to lower LDL cholesterol in adultsThe U.S. Food and Drug Administration has approved Lipfendra (enlicitide), the first oral inhibitor of the PCSK9 protein, for use as an adjunct to diet and exercise in adults with high cholesterol,…